Serina Therapeutics, Inc.
SER evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SER—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SER
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company focused on developing therapeutics based on its proprietary polymer technology platform, with its lead product candidate SER-252 targeting neurodegenerative diseases.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Serina Therapeutics, Inc..
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company focused on developing therapeutics based on its proprietary polymer technology platform, with its lead product candidate SER-252 targeting neurodegenerative diseases.
- Serina Therapeutics is advancing its lead product candidate SER-252 toward Phase I clinical trials [sec_mda · as of 2026-08-13].
- The company has cash and equivalents of $23.0M as of 2026-06-30 [sec].
- Serina reported a net loss of -$6.4M for the period ending 2026-06-30 [sec].
- The company expects to continue incurring net losses and anticipates expenses will increase as it advances its pipeline [sec_mda · as of 2026-08-13].
- Serina's future capital requirements depend on factors including the progress and costs of IND-enabling studies and clinical trials for SER-252 [sec_mda · as of 2026-08-13].
What works
- Serina has a proprietary polymer technology platform that underpins its product candidates, providing a potential structural advantage in drug delivery [sec_mda · as of 2026-08-13].
- The company is advancing its lead candidate SER-252 into Phase I trials, indicating progress toward clinical development [sec_mda · as of 2026-08-13].
- Serina holds cash of $23.0M as of 2026-06-30, providing near-term funding for planned activities [sec].
What to weigh
- Serina has no approved products and has generated zero revenue as of 2026-06-30 [sec].
- The company has a history of net losses, with a net loss of -$6.4M for the period ending 2026-06-30 [sec].
- Serina expects to need additional financing to continue development and may need to delay, reduce, or terminate activities if unable to secure funding [sec_mda · as of 2026-08-13].
- The company faces significant risks related to regulatory approval, clinical trial outcomes, and competition [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Serina's lead product candidate is SER-252, which is being advanced into Phase I clinical trials.
“advance our lead product candidate, SER 252 into Phase I clinical trials”
SEC MD&A · March 25, 2026
The company expects to continue incurring net losses and needs additional financing.
“We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.”
SEC MD&A · August 13, 2026
Serina's future funding requirements depend on multiple factors including clinical trial progress and regulatory outcomes.
“Our future funding requirements will depend on many factors, including, but not limited to: • the progress, costs and results of IND enabling studies for our lead product candidate SER-252 and our potential future clinical trials for SER-252”
SEC MD&A · August 13, 2026
Serina may need to delay, reduce, or terminate planned activities if additional financing is not obtained.
“will need to delay, reduce, or terminate planned activities to reduce costs.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Serina has no commercial products and reported zero revenue as of 2026-06-30 [sec].
- Need for additional financing — The company expects to require additional financing to continue development and may need to delay or terminate activities if unable to secure funds [sec_mda · as of 2026-08-13].
- Clinical and regulatory uncertainty — Serina's product candidates may fail in clinical trials or fail to obtain regulatory approval, which could materially impact the company [sec_mda · as of 2026-08-13].
- History of net losses — Serina has incurred net losses, including a net loss of -$6.4M for the period ending 2026-06-30, and expects losses to continue [sec].
What to watch
- Progress of IND-enabling studies and initiation of Phase I clinical trials for SER-252 [sec_mda · as of 2026-08-13].
- Ability to secure additional financing to support ongoing operations and development [sec_mda · as of 2026-08-13].
- Updates on regulatory interactions with the FDA regarding SER-252 and other product candidates [sec_mda · as of 2026-08-13].
- Changes in cash position and burn rate as the company advances its pipeline [sec].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Serina Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Serina Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
10.6 months
OCF -$7M · Net income -$6M
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
7 buys · 2 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$1.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 318,272 | $617K |
| geode capital management, llc | 64,973 | $126K |
| blackrock, inc. | 58,264 | $113K |
| jane street group, llc | 39,653 | $77K |
| vanguard fiduciary trust co | 20,009 | $39K |
| state street corp | 12,758 | $25K |
| caitong international asset management co., ltd | 3,982 | $8K |
| wells fargo & company/mn | 3,606 | $7K |
| osaic holdings, inc. | 1,001 | $2K |
| tower research capital llc (trc) | 843 | $2K |
Showing top 10 of 21 institutional holders of Serina Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 7.1%
- Days to cover
- 0.1
- Shares short
- 478,077
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SER short interestGovernance
Frequently asked questions
What is the AI investment thesis for Serina Therapeutics, Inc.?
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company focused on developing therapeutics based on its proprietary polymer technology platform, with its lead product candidate SER-252 targeting neurodegenerative diseases.
What is Serina Therapeutics, Inc.'s lead drug candidate?
Serina Therapeutics, Inc.'s most advanced tracked candidate is ser 214 (Phase 1) for Early Parkinson's and Restless Leg Syndrome.
Who is the CEO of Serina Therapeutics, Inc.?
Mr. Steven A. Ledger is the chief executive officer of Serina Therapeutics, Inc. (SER).
Where is Serina Therapeutics, Inc. headquartered?
Serina Therapeutics, Inc. (SER) is headquartered in Huntsville, AL, United States.
What therapeutic areas does Serina Therapeutics, Inc. focus on?
Serina Therapeutics, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.